AK114

AK114 is a monoclonal antibody that targets interleukin-1 beta (IL-1β), acting as an IL-1β inhibitor. It was developed by Akeso Biopharma for the treatment of inflammatory diseases, autoimmune disorders, eye disorders, and has also been investigated in oncology for advanced or metastatic solid tumors. The drug’s mechanism involves neutralizing IL-1β, a pro-inflammatory cytokine implicated in various immune-mediated and neoplastic conditions. As of the latest updates, clinical development has included Phase 1 trials in oncology (solid tumors), but development for autoimmune and eye disorders appears to have been discontinued[1][2][4][5].